1. Medtech Insight
  2. >>Business
  3. >>Deals

Dexcom Rumored To Be In Talks To Acquire Insulet

 
• By Barnaby Pickering

Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.

Dexcom's HQ in San Diego, California • Source: Shutterstock

DexCom is reported to be in talks with Insulet to acquiring the insulin pump manufacturer, as reported by Bloomberg on 23 May.

The deal, which would combine Dexcom’s $31.8bn market cap with Insulet’s $14.1bn market cap, would form an indisputable giant in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

INBRAIN, Mayo Clinic To Test BCI With Standard Deep Brain Stimulation In Parkinson’s Patients

Barcelona-based INBRAIN Neuroelectronics is partnering with Mayo Clinic to test whether its graphene-based cortical brain computer interface can enhance standard DBS in Parkinson’s, aiming for more precise adaptive therapy and improved gait outcomes.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 
• By Natasha Barrow

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

Deals Shaping The Medtech And Diagnostics Industries, August 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

More from Business

Mendaera’s Handheld Robotic System Poised To ‘Transform Needle-Based Procedures’ Starting In Urology

 
• By Marion Webb

After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 
• By Natasha Barrow

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

Doug Godshall Takes Helm At Galvanize As $100M Round Fuels Next Phase Of PEF Development

 
• By Shubham Singh

Galvanize will use its $100m Series C funding to expand commercial operations and advance Aliya PEF in oncology and RheOx in chronic bronchitis, while continuing to refine its nonthermal PEF platform, which delivers short electrical pulses to disrupt disease processes.